PERSISTENCE WITH FINGOLIMOD VERSUS DIMETHYL FUMARATE IN PATIENTS WITH MULTIPLE SCLEROSIS: RETROSPECTIVE ANA LYSIS OF US OPEN-SOURCE PHARMACY DATA

被引：3
|
作者：
Bergvall, N. [1 ]
Lahoz, R. [1 ]
Nazareth, T. [2 ]
Korn, J. R. [3 ]
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] IMS Hlth, Waltham, MA USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.912
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND58
引用
收藏
页码：A400 / A400
页数：1
相关论文
共 50 条
  • [31] Multiple sclerosis patients initiating dimethyl fumarate versus fingolimod in the real-world setting have baseline characteristics associated with worse clinical prognosis
    Hersh, C.
    Lei, Y.
    de Moor, C.
    Rudick, R.
    Williams, J. R.
    Kieseier, B.
    Koulinska, I.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 866 - 867
  • [32] Lymphopenia in patients on dimethyl fumarate (DMF): data from the providence multiple sclerosis center
    Smoot, K. E.
    Chen, C.
    Baraban, E.
    Grote, L.
    Kresa-Reahl, K.
    Cohan, S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 292 - 293
  • [33] Efficacy of oral fingolimod versus dimethyl fumarate on measures of freedom from disease activity in patients with multiple sclerosis, based on indirect comparisons of phase 3 trials
    Bergvall, N.
    Nixon, R.
    Tomic, D.
    Sfikas, N.
    Cutter, G.
    Giovannoni, G.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 519 - 519
  • [34] Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count
    Baharnoori, M.
    Gonzalez, C. T.
    Chua, A.
    Diaz-Cruz, C.
    Healy, B. C.
    Stankiewicz, J.
    Weiner, H. L.
    Chitnis, T.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 20 : 51 - 57
  • [35] A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod
    Salter, Amber
    Lancia, Samantha
    Cutter, Gary
    Marrie, Ruth Ann
    Mendoza, Jason P.
    Lewin, James B.
    Mellen, Robert J. Fox
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [36] Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study
    Vieira, Maria Cecilia
    Conway, Devon
    Cox, Gina Mavrikis
    Peeples, Miranda
    Bensimon, Arielle G.
    Macheca, Monica
    Herrera, Vivian
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (02) : 261 - 270
  • [37] Persistence and adherence of fingolimod compared with other disease modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis
    Bergvall, N.
    Lahoz, R.
    Agashivala, N.
    Pradhan, A.
    Capkun-Niggli, G.
    Korn, J. R.
    Petrilla, A. A.
    Karkare, S. U.
    McGuiness, C. Balderston
    Makin, C.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 520 - 521
  • [38] Effect of comorbidities on dimethyl fumarate persistence and effectiveness in patients with relapsing remitting multiple sclerosis in a real world clinic setting
    Campbell, T. L.
    Stadnyk, K.
    Park, D.
    Beattie, A.
    Mckelvey, R.
    Bhan, V.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 636 - 637
  • [39] Rate of cardiovascular disease among Swedish multiple sclerosis patients treated with rituximab, natalizumab, fingolimod, and dimethyl fumarate: a nationwide cohort study
    Frisell, T.
    Cuijpers, M.
    Piehl, F.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 314 - 314
  • [40] Time to treatment failure following initiation of fingolimod versus teriflunomide for the treatment of multiple sclerosis: a retrospective US claims study
    da Silva, Maria Cecilia Vieira
    Conway, Devon
    Cox, Gina
    Signorovitch, James
    Peeples, Miranda
    Bensimon, Arielle
    Herrera, Vivian
    NEUROLOGY, 2018, 90
12345